Pauline Brice

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

Barbara Pro, Ranjana H. Advani, Pauline Brice et al. · Journal of Clinical Oncology · 2012 · 990 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Marc André, T. Girinsky, Massimo Federico et al. · Journal of Clinical Oncology · 2017 · 532 citations · Full text

Medicine, Oncology, Pharmacology +17

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome

Corinne Haïoun, Emmanuel Itti, Alain Rahmouni et al. · Blood · 2005 · 497 citations · Full text

Medicine, Nuclear Medicine, Oncology +16

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Franck Morschhauser, Nathan Fowler, Pierre Feugier et al. · New England Journal of Medicine · 2018 · 362 citations · Full text

Medicine, Oncology, Pharmacotherapy +15